We investigated the release of chloroquine (Clq) as a model DMAR drug encapsulated in enzyme-mediated polyphenylalanine nanotubes (Clq-Nt) using primary cultures of synovial cells from OA inpatients undergoing total knee replacement. The Clq-Nts were also embedded in an injectable vehicle containing hyaluronic acid (Clq-Nt-HA). Clq-Nt and Clq-Nt-HA samples reduced 62 and 37.5 % the concentration of IL-1β, respectively. For TNF-α the reduction was 38 and 26 %, and for IL-6 was 17.1 and 10 % for Clq-Nt and Clq-Nt-HA, respectively. Additionally, Clq-Nt and Clq-Nt-HA allowed cell viability and proliferation of the synoviocytes according to MTT and CaAM/EthD-1 assays after fifteen days exposure. Micrographs of crystal violet assay also assess the adequate morphologies for synoviocytes treated with Clq-loaded in the tubes. The production of intracellular radical oxygen species (ROS), and extracellular H2O2 and nitrites was also investigated with the inpatient synoviocyte cells with and without treatments which showed no significant differences. Additionally, the apparent viscosity with the shear rate and viscoelastic properties in the injectable fluid containing the encapsulated drug Clq-Nt-HA showed no significant variation with control viscous fluid with only HA, and it falls within the synovial fluid viscosity range for arthritis patients.